Welcome to our dedicated page for Rapt Therapeutics SEC filings (Ticker: RAPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The RAPT Therapeutics, Inc. (Nasdaq: RAPT) SEC filings page on Stock Titan provides access to the company’s official reports and disclosures filed with the U.S. Securities and Exchange Commission. As a clinical-stage immunology-based biopharmaceutical company focused on inflammatory and immunological diseases, RAPT uses SEC filings to report financial results, capital-raising activities and other material corporate events.
Investors can review current and historical Form 8-K filings in which RAPT reports items such as quarterly and year-to-date financial results, underwritten public offerings of common stock, and changes to its board of directors and governance arrangements. For example, recent 8-K filings have furnished press releases detailing net losses, research and development and general and administrative expenses, cash and marketable securities balances, and the terms and expected proceeds of a public equity offering intended to fund operations into 2028 based on the company’s stated operating plans.
Beyond 8-Ks, RAPT’s broader SEC reporting (such as Forms 10-Q and 10-K, referenced in its press releases) contains more extensive discussions of risk factors, pipeline programs, clinical trial status and accounting policies. These periodic reports are important for understanding how the company describes its clinical-stage immunology-based business model, including programs like ozureprubart and other early-stage assets, as well as its assessment of capital needs and potential risks.
On Stock Titan, SEC filings are updated in near real time as they are posted to the EDGAR system. AI-powered summaries help explain the key points of lengthy documents, highlighting items such as changes in operating expenses, financing transactions, and material clinical or regulatory disclosures described in attached press releases or narrative sections. Users can quickly scan these summaries before diving into the full text of a filing.
For those tracking executive and director matters, RAPT’s filings also include information on board appointments, committee assignments and compensation policies, as seen in governance-related 8-K disclosures. Together, these documents provide a structured record of how RAPT communicates its financial condition, capital structure and development progress to regulators and the market.
RAPT Therapeutics President and CEO Brian Russell Wong received a significant stock option grant on June 20, 2025. The derivative securities transaction involved:
- Grant of 637,500 stock options to purchase common stock
- Exercise price set at $7.43 per share
- Options expire on June 19, 2035
- Vesting schedule: 1/48th of shares vest monthly starting June 20, 2025
This Form 4 filing discloses the equity-based compensation grant to Wong, who serves as both Director and CEO. The substantial option grant, which represents direct ownership, appears to be part of the company's executive compensation strategy to align management interests with shareholders over a long-term ten-year period.
RAPT Therapeutics Chief Financial Officer Rodney Young received a significant stock option grant on June 20, 2025. The derivative securities transaction involves:
- Grant of 118,750 stock options to purchase common stock
- Exercise price set at $7.43 per share
- Options expire on June 19, 2035
- Vesting schedule: 1/48th of shares vest monthly starting June 20, 2025
This Form 4 filing indicates a standard executive compensation arrangement through equity incentives. The 10-year option grant with monthly vesting over 4 years suggests a long-term retention strategy for the CFO. The direct ownership structure of these derivatives aligns with typical executive compensation practices.
RAPT Therapeutics Chief Scientific Officer Dirk G. Brockstedt received a new stock option grant on June 20, 2025. The derivative securities transaction details include:
- Grant of 100,000 stock options to purchase common stock
- Exercise price set at $7.43 per share
- Options expire on June 19, 2035
- Vesting schedule: 1/48th of shares vest monthly from June 20, 2025
This Form 4 filing represents a standard equity compensation grant to a senior executive, likely as part of the company's long-term incentive program. The 10-year option term and 4-year monthly vesting schedule are typical for executive compensation in the biotech industry, designed to promote long-term retention and align management interests with shareholders.
RAPT Therapeutics (Nasdaq: RAPT) filed an 8-K reporting governance changes effective June 21 2025.
The Board expanded from five to seven directors and appointed Scott Braunstein, M.D. and Ashley Dombkowski, Ph.D. as Class III directors, with terms running through the 2028 annual meeting. Dr. Braunstein joins the Audit Committee, while Dr. Dombkowski joins the Nominating & Corporate Governance Committee.
The filing also notes an amendment to the non-employee director compensation policy; new directors now receive a one-time option grant for 25,000 common shares. Both directors executed standard indemnification agreements, and the company states that no related-party transactions exist under Item 404(a).